duloxetine has been researched along with nomifensine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, JP; Crocker, PJ; Curry, MA; Harms, AE; Hassler, C; Kitchen, DB; Klos, AM; Laws, M; Liu, S; Molino, BF; Olson, RE; Opalka, C; Pechulis, AD; Smith, MA; Sweet, MP; Vellekoop, AS; Wolf, MA; Xi, N; Yang, Z | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for duloxetine and nomifensine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for duloxetine and nomifensine
| Article | Year |
|---|---|
4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.
Topics: Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Kinetics; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Tetrahydroisoquinolines | 2012 |